

PRESS RELEASE

BRAIN AG Presents New Strategy at Capital Markets Day

B.R.A.I.N. Biotechnology Research and Information Network AG (BRAIN AG; ISIN DE0005203947 / WKN 520394) has today successfully hosted its second Capital Markets Day (CMD) for analysts and institutional investors at the technology campus in Zwingenberg, Germany. BRAIN's management there communicated the strategy on the basis of which the biotech company intends to continue its successful growth path.

The event was also webcasted to allow a maximum attendance in times of the Corona pandemic. Around 60% of the BRAIN AG shareholder capital has participated in the event.

Strategic Targets and Focused New Business Development Pipeline Presented

BRAIN AG management presented the strategic pillars for its future success. The company will emphasize the growth of its products-based business, maintain its strong research foundation and remain a strong development partner for industrial biotechnology through its tailor made solutions (TMS). With the transformation of the products-based business from a purchase for resale model to own production and fermentation BRAIN management believes it can create significant value upside. Selective M&A might accelerate these strategic targets. In this way BRAIN aims to continue its successful growth path.

In addition, a focused new business development pipeline was presented. BRAIN AG will focus its scientific and financial resources on the most

Zwingenberg, Germany
September 15th, 2020

B.R.A.I.N.
Biotechnology Research
And Information Network AG
Darmstädter Str. 34-36
64673 Zwingenberg
Germany
www.brain-biotech.com

Contact Investor Relations
Michael Schneiders
Phone: +49-6251-9331-86
Email: mis@brain-biotech.com

Media Contact
Dr. Stephanie Konle
Phone: +49-(0)-6251-9331-70
Email: stk@brain-biotech.com

B·R·A·I·N

promising projects with the aim to meet customer needs, shorten the time to market and optimize the value. These projects address the big societal topics of nutrition, health and the environment.

Adriaan Moelker, CEO BRAIN AG, states: "My management team and I were very pleased by the strong attendance at our CMD and the intensive dialogue with our shareholders. We have now clearly set and communicated a mid-term corporate strategy. Brain AG will significantly grow its products-based business while remaining committed to developing breakthrough solutions based on our deep scientific foundation."

New Mid-Term Targets Announced

BRAIN AG has also communicated new mid-term targets. The company plans to double revenues from the base in fiscal year '18/'19 and achieve an EBITDA margin of 15% (+/-5%) over the next four to five years. In addition, BRAIN aims to achieve a proportion of new product sales around 30% of total revenues.

Lukas Linnig, BRAIN's new CFO from Oct. 1st, says: "It is very important for us to keep our shareholders on top of recent developments and our next strategic steps. Our mid-term targets are ambitious but fully backed by our development plan."

All presentation material is available in the investor relations section of the BRAIN website.

Presentations Capital Markets Day:

<https://www.brain-biotech.com/investors/capital-markets-day>

Financial Publications:

<https://www.brain-biotech.com/investors/financial-publications/2019-20>

Financial Calendar:

<https://www.brain-biotech.com/investors/financial-calendar>

B·R·A·I·N

About BRAIN

B.R.A.I.N. Biotechnology Research and Information Network AG (BRAIN AG; ISIN DE0005203947 / WKN 520394) is one of Europe's leading technology companies in the field of industrial biotechnology, the core discipline of the bioeconomy. As such, BRAIN identifies previously untapped efficient enzymes, microbial producer organisms or natural substances from complex biological systems that can be put to industrial use. The innovative solutions and products developed by means of "Nature's Toolbox" are successfully applied in the chemicals, cosmetics and food industries.

BRAIN's business model is based on two pillars. The BioScience segment mainly comprises research and development business with industrial partners, and the company's own research and development. The BioIndustrial segment consists mainly of business with industrially scalable products. As part of a growth-oriented industrialization strategy, BRAIN AG has been listed on the Prime Standard of the Frankfurt Stock Exchange since February 2016 as the first company in the bioeconomy. Further information is available at www.brain-biotech.com.

Disclaimer

This press release contains forward-looking statements. These statements reflect the current views, expectations, and assumptions of the management of BRAIN AG and are based on information currently available to the management. Forward-looking statements are no guarantees of future performance and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. There are numerous factors which could influence the future performance by and future developments at BRAIN AG and the BRAIN group of companies. Such factors include, but are not limited to, changes in the general economic and competitive environment, risks associated with capital markets, currency exchange rate fluctuations, changes in international and national laws and regulations, in particular with respect to tax laws and regulations, and other factors. BRAIN AG does not undertake any obligation to update or revise any forward-looking statements.

Follow BRAIN AG on Twitter (Twitter@BRAINbiotech) and LinkedIn (@BRAIN AG)